Basic Medicine, Molecular and Cellular Biology, Oncology

Pathology and Histotechnology

Analysis of Hormone Actions in Breast Cancer

Health Sciences Course

  • Master / Doctoral Degree

Faculty

SUZUKI, TakashiSUZUKI, Takashi
SUZUKI, Takashi

Professor, M.D. Ph.D.

  • TEL

    +81-22-717-8677

  • Mail

    t-suzuki*patholo2.med.tohoku.ac.jp (Please convert "*" into "@".)

*Concurrent Position

Research Theme

  • Analysis of invasion and metastatic processes in breast cancer
  • Analysis of resistance mechanisms after endocrine therapy and/or chemotherapy in breast cancer
  • Analysis of hormone actions in various human cancers
Research Keywords:

breast cancer, hormone, invasion, metastasis, treatment

Technical Keywords:

immunohistochemistry, pathology, microarray, cell culture, animal experiment

Laboratory Introduction

Breast cancer is one of the most common malignancies in women worldwide. Therefore, it is very important to investigate biological features of breast carcinoma in order to improve clinical outcome of the patients. It is well known that estrogens play important roles in the development of human breast carcinomas, and endocrine therapies are frequently used in these patients to block the intratumoral estrogen actions. In the Division of Pathology and Histotechnology, we analyze hormone actions in breast carcinoma by pathological methods as well as various molecular biological techniques.

Figure 1. <i>in situ</i> estrogen synthesis in breast carcinoma tissue

Figure 1. <i>in situ</i> estrogen synthesis in breast carcinoma tissue

Figure 2. Identification of molecular mechanism of estrogen-mediated invasion

Figure 2. Identification of molecular mechanism of estrogen-mediated invasion

Recent Publications

  • CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance. Cancer Sci 2016. (in press)
  • TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression. Nat Commun 6:8219, 2015.
  • Abnormal expression of miR-1 in breast carcinoma as a potent prognostic factor. Cancer Sci 106: 1642-50, 2015.
  • NRF2 immunolocalization in human breast cancer patients as a prognostic factor. Endocr Relat Cancer 21: 241-52, 2014.
  • CtBP2 modulates the androgen receptor to promote prostate cancer progression. Cancer Res 74: 6542-53, 2014.